Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia

Blood Adv. 2020 Oct 27;4(20):5089-5092. doi: 10.1182/bloodadvances.2020003087.

¹ Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA.
² Department of Medicine, Harvard Medical School, Boston, MA.
³ Division of Medical Oncology, University of Washington, Seattle, WA.
⁴ Division of Hematology and Oncology, Mayo Clinic, Rochester, MN.
⁵ Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.
⁶ Department of Pathology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA; and.
⁷ UW Hematopathology Laboratory, Department of Laboratory Medicine, University of Washington, Seattle, WA.

Abstract

Daratumumab was associated with an overall response of 23% and a median PFS of 2 months in previously treated patients with WM.
The 2 patients who attained a partial response to daratumumab exhibited higher baseline CD38 median fluorescent intensity in plasma cells.